The DOI matches its Crossref record; 163 of the 163 references it cites were found in a registry or an index.
Noncoding RNAs in gastric cancer: implications for drug resistance
Open accessAbstract
Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide. Advanced gastric cancer patients can notably benefit from chemotherapy including adriamycin, platinum drugs, 5-fluorouracil, vincristine, and paclitaxel as well as targeted therapy drugs. Nevertheless, primary drug resistance or acquisition drug resistance eventually lead to treatment failure and poor outcomes of the gastric cancer patients. The detailed mechanisms involved in gastric cancer drug resistance have been revealed. Interestingly, different noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), are critically involved in gastric cancer development. Multiple lines of evidences demonstrated that ncRNAs play a vital role in gastric cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically summarized the emerging role and detailed molecular mechanisms of ncRNAs impact drug resistance of gastric cancer. Additionally, we propose the potential clinical implications of ncRNAs as novel therapeutic targets and prognostic biomarkers for gastric cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
7 retracted
Zhang, J., Xu, Y., Gao, Y., Chen, C., Zheng, Z.-S., Yun, M., Weng, H.-W., Xie, D., & Ye, S. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0586-y · Cited by 88
Self-citationRetractedLiu, X., Ru, J., Zhang, J., Zhu, L.-H., Liu, M., Li, X., & Tang, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064707 · Cited by 58
RetractedShen, J., Niu, W., Zhang, H., Jun, M., & Zhang, H. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x15061902533715 · Cited by 46
RetractedmiR-135a promotes gastric cancer progression and resistance to oxaliplatin
Yan, L., Chen, Z.-N., Li-Li, L.-L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12208 · Cited by 36
RetractedLi, B., Wang, L., Li, Z., Wang, W., Zhi, X., Huang, X., Zhang, Q., Chen, Z., Zhang, X., He, Z., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.10.008 · Cited by 35
RetractedXu, Y., Liu, X., Li, M., Li, Y., Li, C., Lü, Y., Sanches, J., Wang, L., Du, Y., Mao, L.-M., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.06.011 · Cited by 26
Self-citationRetractedSong, A., Zhao, L., Wang, Y., He, D., & Li, Y. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28812 · Cited by 15
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Cited by
Pyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Lin, Z., Wu, Y., Xu, Y., Li, G., Li, Z., & Liu, T. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01650-5 · Cited by 297
Self-citation
Metadata
- Authors
- Wei, L., Sun, J., Zhang, N., Zheng, Y., Wang, X., Lv, L., Liu, J., Xu, Y., Shen, Y., & Yang, M.
- Venue
- Molecular Cancer
- Published
- 2020-03-19
- Volume
- 19
- Issue
- 1
- Pages
- 62-62
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W3012821548
- Cited by
- 468
- References
- 163
- FWCI
- 19.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noncoding RNAs in gastric cancer: implications for drug resistance. https://app.cochat.ai/papers/10.1186/s12943-020-01185-7
- The paper
- Wei, L., Sun, J., Zhang, N., Zheng, Y., Wang, X., Lv, L., Liu, J., Xu, Y., Shen, Y., & Yang, M. (2020). Noncoding RNAs in gastric cancer: implications for drug resistance. Molecular Cancer. https://doi.org/10.1186/s12943-020-01185-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.